558 related articles for article (PubMed ID: 20492837)
1. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.
Winhusen TM; Somoza EC; Brigham GS; Liu DS; Green CA; Covey LS; Croghan IT; Adler LA; Weiss RD; Leimberger JD; Lewis DF; Dorer EM
J Clin Psychiatry; 2010 Dec; 71(12):1680-8. PubMed ID: 20492837
[TBL] [Abstract][Full Text] [Related]
2. Treating nicotine dependence by targeting attention-deficit/ hyperactivity disorder (ADHD) with OROS methylphenidate: the role of baseline ADHD severity and treatment response.
Nunes EV; Covey LS; Brigham G; Hu MC; Levin FR; Somoza EC; Winhusen TM
J Clin Psychiatry; 2013 Oct; 74(10):983-90. PubMed ID: 24229749
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
[TBL] [Abstract][Full Text] [Related]
5. Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD.
Luo SX; Covey LS; Hu MC; Winhusen TM; Nunes EV
Am J Addict; 2019 Nov; 28(6):497-502. PubMed ID: 31538372
[TBL] [Abstract][Full Text] [Related]
6. Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate.
Covey LS; Hu MC; Weissman J; Croghan I; Adler L; Winhusen T
Nicotine Tob Res; 2011 Oct; 13(10):1003-8. PubMed ID: 21652734
[TBL] [Abstract][Full Text] [Related]
7. OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences.
Covey LS; Hu MC; Winhusen T; Weissman J; Berlin I; Nunes EV
Drug Alcohol Depend; 2010 Jul; 110(1-2):156-9. PubMed ID: 20219292
[TBL] [Abstract][Full Text] [Related]
8. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
[TBL] [Abstract][Full Text] [Related]
9. An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder.
Covey LS; Hu MC; Green CA; Brigham G; Hurt RD; Adler L; Winhusen T
Am J Drug Alcohol Abuse; 2011 Sep; 37(5):392-9. PubMed ID: 21854282
[TBL] [Abstract][Full Text] [Related]
10. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
[TBL] [Abstract][Full Text] [Related]
12. Anxiety and Depressed Mood Decline Following Smoking Abstinence in Adult Smokers with Attention Deficit Hyperactivity Disorder.
Covey LS; Hu MC; Winhusen T; Lima J; Berlin I; Nunes E
J Subst Abuse Treat; 2015 Dec; 59():104-8. PubMed ID: 26272693
[TBL] [Abstract][Full Text] [Related]
13. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
[TBL] [Abstract][Full Text] [Related]
14. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
[TBL] [Abstract][Full Text] [Related]
15. Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder.
Luo SX; Wall M; Covey L; Hu MC; Scodes JM; Levin FR; Nunes EV; Winhusen T
Am J Drug Alcohol Abuse; 2018; 44(6):653-659. PubMed ID: 29370538
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
[TBL] [Abstract][Full Text] [Related]
18. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.
Rösler M; Fischer R; Ammer R; Ose C; Retz W
Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):120-9. PubMed ID: 19165529
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder.
Reimherr FW; Williams ED; Strong RE; Mestas R; Soni P; Marchant BK
J Clin Psychiatry; 2007 Jan; 68(1):93-101. PubMed ID: 17284136
[TBL] [Abstract][Full Text] [Related]
20. Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial.
Hurt RD; Ebbert JO; Croghan IT; Schroeder DR; Sood A; Hays JT
J Negat Results Biomed; 2011 Jan; 10():1. PubMed ID: 21276244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
